Major Ozempic study fails as Novo Nordisk reveals lackluster results
Major Ozempic Alzheimer’s trial fails
- Novo Nordisk's oral semaglutide drug, Rybelsus, failed to meet its primary goal in late-stage trials assessing its ability to slow cognitive decline in Alzheimer's patients.
- The trial's failure resulted in a 10 per cent drop in Novo Nordisk's share price and represents a setback for hopes that GLP-1 medicines could expand into the Alzheimer's treatment market.
- Rybelsus, which contains semaglutide, is currently approved solely for type 2 diabetes, similar to the company's blockbuster drugs Ozempic and Wegovy.
- Despite the Alzheimer's trial outcome, Novo Nordisk affirmed that semaglutide continues to offer benefits for individuals with type 2 diabetes, obesity, and associated comorbidities.
- The results reinforce analyst scepticism about Novo Nordisk's Alzheimer's ambitions, contrasting with other recently launched treatments from companies like Eli Lilly that have shown some success in slowing cognitive decline.
Bookmark popover
Removed from bookmarks